Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE

The American journal of geriatric pharmacotherapy4 Nov 2011Cited by 43 (Europe PMC)

PMID22055210DOI10.1016/j.amjopharm.2011.09.007PepBankPUB-22055210

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients aged 65 or older with type 2 diabetes, liraglutide 1.8 mg reduced HbA1c more than placebo.
In plain wordsIn adults aged 65 or older with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction, liraglutide 1.8 mg, age 65 or older
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c least squares mean difference
0.91%
>=65 years, 1.8 mg vs placebo
Source sentences
Summary
Reduction in HbA(1c) from baseline was significantly greater with liraglutide 1.8 mg versus placebo (least squares mean difference: ≥65 years, 0.91% [95% CI, 0.69-1.12]; <65 years, 1.17% [95% CI, 1.06-1.28]; both, P < 0.0001) and with liraglutide 1.2 mg versus placebo (≥65 years, 0.87% [95% CI, 0.64…
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521001
02HumanRandomized controlled trialEfficacy outcome
In patients under 65 with type 2 diabetes, liraglutide 1.8 mg reduced HbA1c more than placebo.
In plain wordsIn adults under 65 with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction, liraglutide 1.8 mg, age under 65
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c least squares mean difference
1.17%
<65 years, 1.8 mg vs placebo
Source sentences
Summary
Reduction in HbA(1c) from baseline was significantly greater with liraglutide 1.8 mg versus placebo (least squares mean difference: ≥65 years, 0.91% [95% CI, 0.69-1.12]; <65 years, 1.17% [95% CI, 1.06-1.28]; both, P < 0.0001) and with liraglutide 1.2 mg versus placebo (≥65 years, 0.87% [95% CI, 0.64…
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521002
03HumanRandomized controlled trialEfficacy outcome
In patients aged 65 or older with type 2 diabetes, liraglutide 1.2 mg reduced HbA1c more than placebo.
In plain wordsIn adults aged 65 or older with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction, liraglutide 1.2 mg, age 65 or older
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c least squares mean difference
0.87%
>=65 years, 1.2 mg vs placebo
Source sentences
Summary
Reduction in HbA(1c) from baseline was significantly greater with liraglutide 1.8 mg versus placebo (least squares mean difference: ≥65 years, 0.91% [95% CI, 0.69-1.12]; <65 years, 1.17% [95% CI, 1.06-1.28]; both, P < 0.0001) and with liraglutide 1.2 mg versus placebo (≥65 years, 0.87% [95% CI, 0.64…
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521003
04HumanRandomized controlled trialEfficacy outcome
In patients under 65 with type 2 diabetes, liraglutide 1.2 mg reduced HbA1c more than placebo.
In plain wordsIn adults under 65 with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than placebo.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction, liraglutide 1.2 mg, age under 65
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · 26 weeksAs given in this study (human).
Measurements
HbA1c least squares mean difference
1.1%
<65 years, 1.2 mg vs placebo
Source sentences
Summary
Reduction in HbA(1c) from baseline was significantly greater with liraglutide 1.8 mg versus placebo (least squares mean difference: ≥65 years, 0.91% [95% CI, 0.69-1.12]; <65 years, 1.17% [95% CI, 1.06-1.28]; both, P < 0.0001) and with liraglutide 1.2 mg versus placebo (≥65 years, 0.87% [95% CI, 0.64…
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521004
05HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, fasting plasma glucose results of liraglutide 1.8 mg or 1.2 mg versus placebo were comparable for both age groups (P < 0.0001).
In plain wordsIn adults with type 2 diabetes, fasting blood sugar results with liraglutide versus placebo were comparable in both age groups.
Peptide
Liraglutide
Outcome
Direction not reportedFasting plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg or 1.2 mg · 26 weeksAs given in this study (human).
Source sentences
Summary
For fasting plasma glucose, comparable results were observed between liraglutide 1.8 mg or 1.2 mg and placebo for both age groups (P < 0.0001).
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521005
06HumanObservational studyEfficacy outcome
In patients with type 2 diabetes treated with liraglutide, body weight change did not differ significantly between the age groups.
In plain wordsIn adults with type 2 diabetes given liraglutide, weight change was not significantly different between older and younger patients.
Peptide
Liraglutide
Outcome
No significant changeBody weight change between age groups
Study
n: not reported in source
Comparator
Younger versus older patients
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
No statistically significant difference in body weight change was seen with liraglutide between the age groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521006
07HumanObservational studySafety outcome
In patients with type 2 diabetes treated with liraglutide, the proportion with minor hypoglycemia was low and comparable between the two age groups.
In plain wordsIn adults with type 2 diabetes given liraglutide, mild low blood sugar was uncommon and similar in older and younger patients.
Peptide
Liraglutide
Outcome
No significant changeMinor hypoglycemia between age groups
Study
n: not reported in source
Comparator
Younger versus older patients
Outcome group
Adverse events · Metabolic and weight
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
The proportion of patients reporting minor hypoglycemia was low and appeared comparable between the ≥65-year-old (4.3%-15.2%) and <65-year-old (8%-13.2%) groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521007
08HumanObservational studySafety outcome
In patients with type 2 diabetes treated with liraglutide, adverse events appeared comparable in nature and frequency between the age groups.
In plain wordsIn adults with type 2 diabetes given liraglutide, side effects looked similar in kind and frequency in older and younger patients.
Peptide
Liraglutide
Outcome
No significant changeAdverse events between age groups
Study
n: not reported in source
Comparator
Younger versus older patients
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 26 weeksAs given in this study (human).
Source sentences
Summary
Likewise, adverse events appeared comparable in nature and frequency.
2 context sentences(design, population, supporting numbers)
Summary · context
A pooled analysis of 6 randomized, placebo-controlled, multinational trials included data from 3967 patients aged18 to 80 years with type 2 diabetes and glycosylated hemoglobin (HbA(1c)) of 7% to 11%.
Summary · context
Of these, 552 patients ≥65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo; 2231 patients <65 years received liraglutide 1.8 mg, liraglutide 1.2 mg, or placebo for 26 weeks.
Report a problemFND-2205521008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials6

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

6 trials · 5 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00518882